Centessa Pharmaceuticals (CNTA) Competitors $15.04 -0.51 (-3.28%) Closing price 04:00 PM EasternExtended Trading$15.04 0.00 (0.00%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CNTA vs. ROIV, TLX, RVMD, BBIO, LEGN, AXSM, BPMC, CYTK, NUVL, and ELANShould you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Roivant Sciences (ROIV), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Cytokinetics (CYTK), Nuvalent (NUVL), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Centessa Pharmaceuticals vs. Roivant Sciences Telix Pharmaceuticals Limited American Depositary Shares Revolution Medicines BridgeBio Pharma Legend Biotech Axsome Therapeutics Blueprint Medicines Cytokinetics Nuvalent Elanco Animal Health Centessa Pharmaceuticals (NASDAQ:CNTA) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends. Which has more volatility & risk, CNTA or ROIV? Centessa Pharmaceuticals has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Which has preferable earnings and valuation, CNTA or ROIV? Roivant Sciences has higher revenue and earnings than Centessa Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M289.35-$151.09M-$1.53-9.83Roivant Sciences$122.59M59.20$4.35B-$0.15-67.80 Is CNTA or ROIV more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% Roivant Sciences -119.54%-14.05%-12.81% Do institutionals and insiders hold more shares of CNTA or ROIV? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 11.6% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in CNTA or ROIV? Roivant Sciences received 22 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 77.94% of users gave Roivant Sciences an outperform vote while only 58.49% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes3158.49% Underperform Votes2241.51% Roivant SciencesOutperform Votes5377.94% Underperform Votes1522.06% Do analysts recommend CNTA or ROIV? Centessa Pharmaceuticals presently has a consensus target price of $25.83, suggesting a potential upside of 71.76%. Roivant Sciences has a consensus target price of $18.08, suggesting a potential upside of 77.81%. Given Roivant Sciences' higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to CNTA or ROIV? In the previous week, Roivant Sciences had 11 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 13 mentions for Roivant Sciences and 2 mentions for Centessa Pharmaceuticals. Roivant Sciences' average media sentiment score of 0.76 beat Centessa Pharmaceuticals' score of 0.29 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Overall Sentiment Centessa Pharmaceuticals Neutral Roivant Sciences Positive SummaryRoivant Sciences beats Centessa Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTA vs. The Competition Export to ExcelMetricCentessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98B$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-9.836.1524.9519.21Price / Sales289.35187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book6.216.447.334.28Net Income-$151.09M$139.03M$3.18B$247.04M7 Day Performance-3.96%-5.52%-4.42%-4.36%1 Month Performance-11.01%-8.56%-6.07%-5.60%1 Year Performance38.36%-14.59%11.42%3.38% Centessa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTACentessa Pharmaceuticals2.2385 of 5 stars$15.04-3.3%$25.83+71.8%+43.1%$1.98B$6.85M-9.83200Short Interest ↑ROIVRoivant Sciences2.3142 of 5 stars$10.52-1.5%$18.08+71.9%-8.8%$7.51B$122.59M-70.13860TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$20.93+7.3%$22.00+5.1%N/A$7.05B$516.72M0.00N/AHigh Trading VolumeRVMDRevolution Medicines4.6581 of 5 stars$41.23-0.3%$66.25+60.7%+36.7%$6.94B$11.58M-11.48250Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBBIOBridgeBio Pharma4.7065 of 5 stars$36.25-1.6%$51.67+42.5%-2.0%$6.85B$221.90M-12.72400Analyst RevisionLEGNLegend Biotech1.9622 of 5 stars$36.98-6.9%$79.50+115.0%-46.6%$6.75B$285.14M-38.931,800Positive NewsAXSMAxsome Therapeutics4.7466 of 5 stars$130.72-5.1%$158.79+21.5%+54.7%$6.37B$385.69M-21.82380Analyst ForecastBPMCBlueprint Medicines2.8663 of 5 stars$92.48+0.2%$123.83+33.9%+1.5%$5.91B$508.82M-85.63640Analyst ForecastCYTKCytokinetics3.9743 of 5 stars$48.14-4.2%$82.00+70.3%-37.8%$5.68B$7.53M-8.95250Earnings ReportAnalyst ForecastAnalyst RevisionNUVLNuvalent2.1402 of 5 stars$78.03-1.8%$113.10+44.9%-14.0%$5.54BN/A-22.4940Earnings ReportAnalyst ForecastELANElanco Animal Health3.6566 of 5 stars$11.14+1.0%$16.00+43.7%-30.2%$5.50B$4.42B27.849,300Earnings ReportAnalyst Revision Related Companies and Tools Related Companies ROIV Alternatives TLX Alternatives RVMD Alternatives BBIO Alternatives LEGN Alternatives AXSM Alternatives BPMC Alternatives CYTK Alternatives NUVL Alternatives ELAN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNTA) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTA Stock Alerts